{
    "Clinical Trial ID": "NCT00295620",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Arm A: Anastrozol",
        "  1 mg per day for 2 years",
        "INTERVENTION 2: ",
        "  Arm B: Anastrozol",
        "  1 mg per day for 5 years"
    ],
    "Eligibility": [
        "Inclusion criteria:",
        "  Postmenopausal patients with histologically confirmed, local radically treated invasive or minimal-invasiv Mammacarcinom with or without previous chemotherapie and/or radiotherapie.",
        "  No distant metastasis at randomization",
        "  No relapse at randomization",
        "  TNM- classification at time of diagnosis: T1-3, N0 and N+, M0",
        "  Estrogen- and or progesterone positive before the beginningof primary endocrine therapy",
        "  Endocrine therapy for 5 years (maximum deviation \u00b112 months)",
        "  Therapy break (from the preliminary therapie) maximum 12 months.",
        "  Informed Consent before the randomisation",
        "Exclusion criteria:",
        "  Premenopausal patients or patients with non definable menopausal statusat time of randomisation",
        "  Apparent secondary malignant tumor or status after secondary malignant tumor (Exceptions: simultaniously appearing bilateral breast carcinoma, estrogen- and or progesteronereceptor positive on both sides at the time of diagnosis; in situ carcinomaof the cervix and basal cell carcinoma of the skin)",
        "  General contraindication respectively hypersensitivity to Anastrozol.",
        "  In-situ carcinoma of any size with or without Mb. Paget of the Mamilla respectively T4 tumor at the time of first diagnosis.",
        "  Receptor unknown or negative at time of diagnosis respectively at beginning of primary endocrine therapy",
        "  Known liver- and/or kidneyinsufficiency",
        "  Performance Index >2 according to WHO",
        "  Regular intake of hormon supplement as well as Hormone Replacement Therapy (HRT) more than 6 months since primary surgery of the mamma carcinoma",
        "  Serious accessory disease, that prevents the adjuvant therapy according to protocol and/or the regular follow-up care.",
        "  Lacking compliance of the patient",
        "  Legal incompetence and/or other circumstances, that prevent the patient from understanding the nature, meaning and consequences of the clinical trial",
        "  Existing psychiatrical diseaseaccording to ICD (especially alcohol addiction) et the time of admission into the study"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Disease-free Survival After Prolonged Endocrine Treatment",
        "  To determine whether 5 years of additional Anastrozole was more effective than 2 years of additional Anastrozole after 5 years of adjuvant endocrine therapy in terms of disease-free survival.",
        "  Time frame: DFS was defined as the time from two years after randomization to the earliest occurrence of loco-regional recurrence, distant recurrence, contralateral new breast cancer, second cancer or death from any cause, assessed up to a maximum of 8.5 years",
        "Results 1: ",
        "  Arm/Group Title: Arm A: Anastrozol",
        "  Arm/Group Description: 1 mg per day for 2 years",
        "  Overall Number of Participants Analyzed: 1281",
        "  Median (Inter-Quartile Range)",
        "  Unit of Measure: Years  NA  [1]    (7.7 to NA)",
        "Results 2: ",
        "  Arm/Group Title: Arm B: Anastrozol",
        "  Arm/Group Description: 1 mg per day for 5 years",
        "  Overall Number of Participants Analyzed: 1323",
        "  Median (Inter-Quartile Range)",
        "  Unit of Measure: Years  NA  [1]    (8.1 to NA)"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 687/1710 (40.18%)",
        "  Anaemia 1/1710 (0.06%)",
        "  Anaemia macrocytic 0/1710 (0.00%)",
        "  Bone marrow oedema 3/1710 (0.18%)",
        "  Haemolytic anaemia 1/1710 (0.06%)",
        "  Immune thrombocytopenic purpura 1/1710 (0.06%)",
        "  Leukopenia 0/1710 (0.00%)",
        "  Lymph node calcification 1/1710 (0.06%)",
        "  Lymphadenitis 1/1710 (0.06%)",
        "  Lymphadenopathy 3/1710 (0.18%)",
        "  Mastocytosis 1/1710 (0.06%)",
        "Adverse Events 2:",
        "  Total: 452/1705 (26.51%)",
        "  Anaemia 1/1705 (0.06%)",
        "  Anaemia macrocytic 1/1705 (0.06%)",
        "  Bone marrow oedema 0/1705 (0.00%)",
        "  Haemolytic anaemia 0/1705 (0.00%)",
        "  Immune thrombocytopenic purpura 0/1705 (0.00%)",
        "  Leukopenia 1/1705 (0.06%)",
        "  Lymph node calcification 0/1705 (0.00%)",
        "  Lymphadenitis 0/1705 (0.00%)",
        "  Lymphadenopathy 0/1705 (0.00%)",
        "  Mastocytosis 0/1705 (0.00%)"
    ]
}